News

Sep 05, 2023 FOSTER CITY, Calif. & SAN DIEGO–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”). In…

Jul 17, 2023 Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal®Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestonesMirum announces concurrent private placement of $210 million, funding upfront paymentExpands Mirum’s leadership in rare liver disease with two commercial…

Oct 07, 2023 – LIVMARLI PFIC primary analysis from MARCH study awarded prestigious Gerard Odell Prize for Excellence in Pediatric Hepatology Research – 15 abstracts demonstrating robust clinical findings from LIVMARLI studies and real-world experience in ALGS and PFIC FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the presentation of a series of analyses demonstrating…

Apr 13, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the…

May 04, 2023 – $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million, for first quarter 2023– Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and…

– Net product sales for LIVMARLI® (maralixibat) oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022 revenue totaled $77.1 million – Conference call to provide business updates today, March 8 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial…